The Sleep in Pregnancy Study



Status:Completed
Conditions:Insomnia Sleep Studies, Obesity Weight Loss, Women's Studies
Therapuetic Areas:Endocrinology, Psychiatry / Psychology, Reproductive
Healthy:No
Age Range:20 - 39
Updated:6/22/2018
Start Date:March 15, 2017
End Date:March 20, 2018

Use our guide to learn which trials are right for you!

Sleep Disordered Breathing Accounts for Abnormal Glycemic Profiles in Pregnant Women: The Sleep in Pregnancy (SiP) Study

Sleep disordered breathing (SDB) insidiously worsens metabolic function, heightens insulin
resistance (IR), and in pregnancy is thought to precipitate gestational diabetes, preterm
birth, growth restriction, gestational hypertension, and preeclampsia. Despite the fact that
sleep disturbances are common during pregnancy, SDB remains under-recognized,
under-diagnosed, and poorly understood, particularly in pregnancies affected by obesity.
Sixty percent of pregnancies are now affected by obesity, yet the relationship between SDB,
patterns of glycemia, and insulin resistance (IR) in obese pregnant women is a neglected area
with major therapeutic implications to improve maternal and infant health. Using a
prospective design in which diet and gestational age are highly controlled, the investigators
propose to measure SDB (apneas/hypopneas) in obese pregnant women using an ambulatory sleep
monitoring system. In parallel, robust patterns of glycemia will be measured with a
continuous glucose monitoring system (CGMS), followed by a 75g oral glucose tolerance test to
measure insulin action. The investigators global hypothesis is that worse SDB in part
accounts for higher 24-hour patterns of glycemia in obese normal glucose tolerant (NGT)
pregnant women in their 3rd trimester. The Investigators will test the hypothesis that: 1) In
obese NGT pregnant women at 32-34 weeks gestation on a controlled eucaloric diet, higher
apnea hypopnea index (AHI) will be positively associated with 24-hour glycemia measured by a
CGMS and that, 2) Higher AHI in obese NGT pregnant women at 32-34 weeks gestation on a
eucaloric controlled diet will be associated with higher insulin resistance measured by a 75g
oral glucose tolerance test (Matsuda Model). Early identification and treatment has the
potential to decrease long-term maternal cardiovascular morbidity and mortality.


Inclusion Criteria:

- Pregnant women:

1. Between the ages of 20-39 yrs,

2. At 32-34 weeks gestation,

3. Who have a BMI of ≥30 to ≤40 kg/m2,

4. Who have a singleton pregnancy, and

5. Who have a normal glucose tolerance test on entrance to the study.

Exclusion Criteria:

- Pregnant Women:

1. Who have a diagnosis of diabetes (GDM, type 1 or type 2),

2. Who are using beta blockers/glucocorticoids.

3. Who have other children who are ≤2 yrs old (due to risk of disrupted sleep),

4. With diagnosed sleep disorders (e.g. OSA, insomnia, restless leg syndrome),

5. Who work night or rotating shifts,

6. Who report use of sleep medications will be excluded,

7. With diagnosed pulmonary or cardiovascular disease

8. Who do not speak English.
We found this trial at
1
site
13001 E 17th Pl
Aurora, Colorado 80045
(303) 724-5000
University of Colorado Anschutz Medical Campus Located in the Denver metro area near the Rocky...
?
mi
from
Aurora, CO
Click here to add this to my saved trials